Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir
- Monini, P
- Sgadari, C
- Grosso, Mg
- Bellino, S
- Di Biagio, A
- Toschi, E
- Bacigalupo, I
- Sabbatucci, M
- Cencioni, G
- Salvi, E
- Leone, P
- Ensoli, B
- Barillari, G
- Moracci, G
- Carratelli, L
- Gatti, G
- Brambilla, L
- Brambati, M
- Ferrucci, S
- De Pita, O
- Pilla, Ma
- Di Carlo, A
- Giuliani, M
- Cottoni, F
- Cuccuru, Ma
- Calvieri, S
- Clerico, R
- Potenza, C
- Tirelli, U
- Simonelli, C
- Martellotta, F
- Strumia, R
- Borghi, A
- Del Giacco, S
- Moi, L
- Piludu, G
- Sirianni, Mc
- Campagna, M
- Sarmati, L
- Andreoni, M
- Bianchini, G
- Sheldon, J
- Milzer, J
- Schulz, T
Publication date
January 2009
DOIAbstract
HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8
Add to ORKG